v3.23.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Total revenue $ 6,712 $ 5,582 $ 12,321 $ 6,414
Operating expenses:        
Cost of sales 1,108 435 1,662 774
Research and development 68,895 74,523 136,196 144,646
Selling, general and administrative 30,409 28,264 58,776 59,779
Total operating expenses 100,412 103,222 196,634 205,199
Loss from operations (93,700) (97,640) (184,313) (198,785)
Royalty income from gain on sale of oncology business 0 2,704 0 5,408
Interest income, net 8,254 1,793 16,345 2,487
Other income, net 1,640 1,337 3,144 4,310
Net loss $ (83,806) $ (91,806) $ (164,824) $ (186,580)
Net (loss) income per share - basic (in usd per share) $ (1.51) $ (1.68) $ (2.97) $ (3.41)
Net (loss) income per share - diluted (in usd per share) $ (1.51) $ (1.68) $ (2.97) $ (3.41)
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - basic (in shares) 55,604,330 54,799,680 55,435,796 54,678,249
Weighted-average number of common shares used in computing net loss per share from continuing operations, net (loss) income from discontinued operations and net (loss) income per share - diluted (in shares) 55,604,330 54,799,680 55,435,796 54,678,249
Product revenue, net        
Revenues:        
Total revenue $ 6,712 $ 3,082 $ 12,321 $ 3,914
Milestone revenue        
Revenues:        
Total revenue $ 0 $ 2,500 $ 0 $ 2,500